Valuation: Vericel Corporation

Market Cap 2.4B 2.1B 1.94B 1.79B 3.4B 230B 3.47B 23.34B 9.07B 112B 9B 8.81B 390B P/E 2026 *
99.4x
P/E 2027 * 53.6x
Enterprise Value 2.4B 2.1B 1.94B 1.79B 3.4B 230B 3.47B 23.34B 9.07B 112B 9B 8.81B 390B EV / Sales 2026 *
7.22x
EV / Sales 2027 * 6.17x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.05%
1 week+4.19%
Current month+5.73%
1 month+31.51%
3 months+38.23%
6 months+15.49%
Current year+30.63%
1 week 45.21
Extreme 45.21
47.79
1 month 36.43
Extreme 36.43
47.79
Current year 28.95
Extreme 28.95
47.79
1 year 28.95
Extreme 28.95
47.79
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 2013-02-28
Director of Finance/CFO 51 2021-01-24
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 71 2005-09-27
Chairman 75 2012-10-04
Director/Board Member 57 2013-08-22
Date Insider Type Main position Quantity % Market Cap.
06-25Sell

Controller/Auditor

-7,732 0.0151%
06-25Fiscal year

General Counsel

45,000 0.0881%
06-25Fiscal year

Chief Technology Officer

30,000 0.0587%
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%+4.19%+17.10%+27.34% 2.4B
-1.75%+6.13%+21.04%-5.74% 68.8B
-2.01%-3.57%+46.21%+217.06% 55.21B
-4.15%+36.30%+36.30%+36.30% 43.46B
+0.27%+8.33%-49.87%-53.43% 41.18B
-6.96%+3.40%+130.38%-39.10% 31.65B
-1.23%-3.56%+50.43%-28.17% 30.37B
-1.06%+2.50%+72.38%+88.48% 23.58B
-1.15%+8.29%+4.42%+184.96% 19.33B
-1.33%+1.11%+66.11%+131.83% 17.16B
Average -1.98%+3.92%+39.45%+55.95% 33.31B
Weighted average by Cap. -2.22%+3.56%+36.47%+50.62%

Financials

2026 *2027 *
Net sales 332M 291M 269M 249M 471M 31.81B 481M 3.23B 1.26B 15.57B 1.25B 1.22B 54.04B 389M 341M 315M 291M 551M 37.22B 562M 3.78B 1.47B 18.21B 1.46B 1.43B 63.22B
Net income 24.64M 21.61M 19.95M 18.44M 34.94M 2.36B 35.64M 240M 93.19M 1.15B 92.52M 90.49M 4.01B 46.36M 40.66M 37.54M 34.69M 65.75M 4.44B 67.07M 451M 175M 2.17B 174M 170M 7.54B
Net Debt - -
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
26-07-08 US$47.00 +0.11% 194,804
26-07-07 US$46.95 +0.84% 422,920
26-07-06 US$46.56 -0.89% 524,531
26-07-02 US$46.98 +4.05% 640,729
26-07-01 US$45.15 +1.48% 613,541
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
46.95USD
Average target price
55.43USD
Spread / Average Target
+18.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VCEL Stock